Compare Qnity Electronics Inc. Common Stock (Q) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Qnity Electronics Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Qnity Electronics Inc. Common Stock trades at $117.97 (market cap $25.44B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Qnity Electronics Inc. Common Stock is far larger — about 6.8× Tango Therapeutics Inc.'s market cap, and Qnity Electronics Inc. Common Stock pays a 0.26% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Qnity Electronics Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| Q | TNGX | |
|---|---|---|
Market Cap | $25.44B | $3.74B |
Volume | 1,971,734 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $175.64 | $32.90 |
52-Week Low | $73.54 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $28.50B | $2.76B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qnity Electronics (Q) trades at $122.95, down 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $4.75B in 2025, though net income margin is expected to dip in 2026. Recent news highlights product launches in AI data center cooling and advanced packaging, alongside inclusion in the PHLX Semiconductor Index.
The stock presents a mixed outlook: strong analyst consensus (100% buy ratings) and a $180 price target suggest significant upside, but technical weakness and a high P/E ratio of 43.9 pose risks. Key opportunities include AI-driven demand and advanced packaging growth, while risks involve execution in a competitive semiconductor market and potential margin pressure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Qnity Electronics Inc. Common Stock
Qnity Electronics provides materials and solutions for semiconductor manufacturing and electronic systems. Its portfolio supports chip fabrication, advanced packaging, interconnects, and thermal management.
Read more on Q →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
